The UK Medicines and Healthcare products Regulatory Agency has authorised the start of human trials for an Ebola vaccine developed by University of Oxford scientists in just eight weeks following the declaration of a public health emergency.
That emergency was declared on 17 May 2026. Work began immediately. The phase one trial, involving 50 healthy UK adults aged 18 to 55, is expected to begin dosing within weeks. Participants will be monitored for a full year. This candidate has reached the clinic ahead of three others still in development.
The vaccine employs the same adenovirus vector technology used in the Oxford-AstraZeneca Covid-19 vaccine. Preclinical testing was completed in mice and macaque monkeys. The Serum Institute of India manufactured the doses to clinical standard and has stockpiled around 620,000 units.
We're doing phase one (early stage) trials of new vaccines all of the time, precisely to be ready for exactly this kind of outbreak.
Those words come from Dr Katrina Pollock, chief investigator of the trial at the University of Oxford. Her team has emphasised that safety protocols remained unchanged. All standard tests were conducted, simply in parallel across multiple sites working around the clock.
As soon as we heard there was an outbreak, we were able to scale up really, really quickly.
Alex Sampson, vaccine researcher at the University of Oxford, described the acceleration. The approach relied on established platforms and private-sector manufacturing agility rather than prolonged state-directed bureaucracy. Such efficiency highlights how targeted investment and institutional capability can deliver results when incentives align with urgent need.
The current outbreak is centred in the Democratic Republic of Congo and is driven by the Bundibugyo species of Ebola virus. It has produced 1,792 laboratory-confirmed cases and 625 deaths. The strain carries a case fatality rate of around one in three. No approved drugs or vaccines exist specifically for it. Control efforts have been hampered by conflict and highly mobile populations in the region. Preparations for related trial work are under way with partners in Uganda.
